134138-88-8

Basic information

• Product Name: Benzoyl chloride, 4-(2-quinolinylmethoxy)-
• CAS NO: 134138-88-8
• Molecular Formula: C17H12ClNO2
• Molecular Weight: 297.741
• Mol File: 134138-88-8.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 4-(2-quinolinylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-(2-quinolinylmethoxy)-(134138-88-8)
• EPA Substance Registry System: Benzoyl chloride, 4-(2-quinolinylmethoxy)-(134138-88-8)

Safety Data

• Hazardous Substances Data: 134138-88-8(Hazardous Substances Data)

Upstream product

• 123724-16-3 4-(quinolin-2-ylmethyloxy)benzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 137426-86-9 4-(2-Quinolinylmethoxy)benzoic acid methyl ester 
• 4377-41-7 2-Chloromethylquinoline 

Downstream Products

• 898562-94-2 2-({4-[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline 
• 898562-93-1 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline 
• 871507-15-2 2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone 
• 871507-16-3 3-(dimethylamino)-2-(pyridin-4-yl)-1-(4-(quinolin-2-ylmethoxy)phenyl)prop-2-en-1-one 
• 871507-11-8 2-((4-(4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline 
• 871507-14-1 N-methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide 

Relevant articles and documents

Development of a Novel Series of (2-Quinolinylmethoxy)phenyl-Containing Compounds as High-Affinity Leukotriene D4 Receptor Antagonists. 4. Addition of Chromone Moiety Enhances Leukotriene D4 Receptor Binding Affinity

The combination of the benzopyran-4-one ring, a moiety found in the prototype leukotriene antagonist, FPL 55,712, with the (2-quinolinylmethoxy)phenyl group led to a significant increase in leukotriene receptor binding affinity.This modification resulted

BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS

The invention pertains to tricyclic heteraaryi compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE 10. The invention further relates to pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.

Heteroaromatic quinoline compounds

The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.